Long-acting injectable antipsychotics in the treatment of schizophrenia: Practical considerations

Karan Kverno, Ilya Rozenberg

Research output: Contribution to journalArticlepeer-review

Abstract

The positive symptoms of schizophrenia are usually treated with oral antipsychotics despite high rates of nonadherence leading to relapse and rehospitalization. Seven long-acting injectable (LAI) antipsychotics are cur-rently approved by the U.S. Food and Drug Administration for maintenance treatment of schizophrenia. These medications reduce the risk for nonad-herence and relapse, yet relatively few clinicians prescribe them. All LAI anti-psychotics are equally effective in treat-ing the positive symptoms of schizo-phrenia. Dosing requirements, dosing frequencies, and what clinicians should consider in choosing a LAI antipsychot-ic for a specific patient are discussed. Communication strategies that help patients and families understand what they need to know about schizophrenia and its treatment to share in the decision-making process are also provided.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalJournal of psychosocial nursing and mental health services
Volume59
Issue number7
DOIs
StatePublished - Jul 2021

ASJC Scopus subject areas

  • General Nursing
  • Phychiatric Mental Health

Fingerprint

Dive into the research topics of 'Long-acting injectable antipsychotics in the treatment of schizophrenia: Practical considerations'. Together they form a unique fingerprint.

Cite this